Erratum to: Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab

Invest New Drugs. 2015 Feb;33(1):269-70. doi: 10.1007/s10637-014-0162-x.

Affiliation

¹ Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong Gangnam-gu, Seoul, 135-710, South Korea.

PMID: 25236593
DOI: 10.1007/s10637-014-0162-x

No abstract available

Publication types

Published Erratum